5J
5JA1.F Sprint Bioscience AB (publ)
- Market cap
- EUR 33.8M
- P/E
- 5.3x
- P/B
- 4.50x
- ROE
- -64.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 5JA1.F undervalued?
Graham number5JA1.F trades 3.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sprint Bioscience AB (publ) fundamental analysis
No fundamental analysis for Sprint Bioscience AB (publ) yet.
Sprint Bioscience AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sprint Bioscience AB (publ)
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherap…
Full company profileSprint Bioscience AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sprint Bioscience AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 35.0M | 24.0M | 17.9M | 33.5M | 16.9M | 35.1M | 799K | 50.5M | 65.6M | 167M | 0.00 |
| Gross Profit | 34.6M | 21.0M | 17.2M | 25.4M | 6.43M | 24.7M | -12.1M | 41.8M | 37.3M | 154M | -9.00M |
| Operating Income | 7.29M | -10.3M | -22.1M | -20.4M | -37.7M | -25.5M | -61.0M | -2.53M | -19.4M | 97.5M | -61.8M |
| EBITDA | - | -10.1M | -21.4M | -19.6M | -38.7M | -24.2M | - | -2.08M | -17.3M | 93.2M | -56.5M |
| Net Income | 4.54M | -10.7M | -22.2M | -21.5M | -42.8M | -25.1M | -60.4M | -438K | -18.3M | 91.7M | -58.2M |
| EPS | - | -1.30 | -2.02 | -1.61 | -2.02 | -0.63 | -0.87 | -0.01 | -0.26 | 0.87 | -0.55 |
| Balance Sheet | |||||||||||
| Total Assets | 49.5M | 35.5M | 59.3M | 19.2M | 33.4M | 79.1M | 37.4M | 62.4M | 42.1M | 137M | 104M |
| Total Liabilities | 21.0M | 7.40M | 22.0M | 8.23M | 24.3M | 8.68M | 9.23M | 34.6M | 32.8M | 17.5M | 14.2M |
| Shareholders' Equity | 28.5M | 28.1M | 37.2M | 11.0M | 9.14M | 70.5M | 28.2M | 27.8M | 9.27M | 119M | 90.1M |
| Cash & Short-term Investments | 23.6M | 1.48M | 14.7M | 8.38M | 27.1M | 70.6M | 29.5M | 49.9M | 25.1M | 127M | 93.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 7.94M | -23.1M | -28.8M | -28.0M | -32.2M | -40.1M | -59.1M | 22.9M | -23.4M | 83.5M | -67.8M |
| Capital Expenditure | 9.91M | 204K | 1.40M | 93.0K | 2.71M | 2.71M | 0.00 | 2.45M | 1.30M | 94.0K | 878K |
| Free Cash Flow | - | -31.6M | -30.2M | -28.1M | -32.2M | -42.8M | -59.0M | 20.4M | -24.7M | 83.4M | -68.7M |
| Ratios | |||||||||||
| ROE | 15.9% | -38.0% | -59.7% | -195.5% | -468.0% | -35.6% | -214.3% | -1.6% | -197.1% | 77.0% | -64.6% |
| ROA | 9.2% | -30.0% | -37.5% | -111.9% | -128.1% | -31.7% | -161.4% | -0.7% | -43.5% | 67.1% | -55.8% |
| Net Profit Margin | 13.0% | -44.5% | -123.9% | -64.2% | -253.4% | -71.4% | -7,560.3% | -0.9% | -27.8% | 54.9% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sprint Bioscience AB (publ) dividends
Sprint Bioscience AB (publ) has not paid dividends in the last 9 fiscal years.
Who owns Sprint Bioscience AB (publ)
- Insiders 27.84%
- Institutions 39.33%
- Public & others 32.83%
- Shares outstanding 106M
- Free float 93.4M
Sprint Bioscience AB (publ) company profile
- Company name
- Sprint Bioscience AB (publ)
- Ticker
- 5JA1.F
- ISIN
- SE0006343745
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 32
- Fiscal year end
- December
- Address
- Novum, Huddinge, Sweden, 141 57
- Phone
- 46 84 11 44 55
- Website
- sprintbioscience.com/sv
About Sprint Bioscience AB (publ)
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and NNMT for the treatment of solid tumors/chronic kidney diseases. It is also developing STK25, which is in preclinical trial to treat metabolic liver disease that can lead to inflammation and fibrosis; and TREX1, which is in preclinical trial for the treatment of solid tumors and immuno-oncology. The company has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases and evaluation of the STK25 program. The company was incorporated in 2009 and is headquartered in Huddinge, Sweden.
Sprint Bioscience AB (publ) management
6- Mr. Johan EmilssonChief Executive Officer · born 1984
- Prof. Pär NordlundFounder · born 1958
- Dr. Martin AnderssonCo-Founder, Research Director & Chief Scientific Officer · born 1971
- Dr. Kenth HallbergFounder & Director of Structural Chemistry · born 1971
- Ms. Jenni BjornulfsonChief Financial Officer · born 1971
- Ms. Anne-Marie WenthzelChief Business Officer · born 1964